Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+small+molecules

157 Results

Sort By:

Dendrimer Conjugated Glutamine Antagonists for Targeted Brain and Tumor Delivery

Value Proposition· Deliver glutamine antagonists to the CNS without GI and systemic toxicity assiated with free DON.· High specificity for activated microglia and tumor-associated macrophages, providing therapeutic precision across neuroinflammatory and oncologic indications. · Broad applicability across CNS, cancer, and immune disorders,...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Rana Rais, Kannan Rangaramanujam, Anjali Sharma, Pavel Majer, Benjamin Bell, Lukas Tenora, Katerina Novotna, Martin Hadzima, Martin Kaiser, Tomas Tichy, Takashi Tsukamoto, Run-Duo Gao, Xiaolei Zhu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

RelA Inhibitor as a Anti-microbial Therapy

Value Proposition:· Unique mechanism of action that targets antibiotic-resistant infections· Ability to target multiple stress resistance mechanisms in bacteria· Broad range of application Technology Description· Researchers at Johns Hopkins have developed an antibacterial small molecule inhibitor that can be used to treat...

Published: 3/13/2026 | Inventor(s): Nathan Archer, Garth Ehrlich, Donald Hall

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases

Tenofovir Spray Drying Sachet Enema Powder Formulation for HIV prevention

#C17178Unmet NeedWorldwide, nearly 2 million people are infected with HIV each year (see UptoDate). In the US specifically, 36,801 people were newly diagnosed with HIV in 2019 (see CDC). Since there is no cure for HIV infection, current best practice involves prevention of infection through pre-exposure prophylaxis (PreP), which can reduce the risk...

Published: 3/13/2026 | Inventor(s): Craig Hendrix, Lisa Rohan, Christina Bagia, Lin Wang

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Sexually-Transmitted Diseases, Technology Classifications > Therapeutic Modalities > Small Molecules

New Therapeutic Approach for the Treatment of Neuropathic Pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Repurposing Perampanel to treat SYNGAP1-related disorders

Value Proposition:· First Targeted Pharmacologic Therapy for SYNGAP1 (MRD5): Introduces the first mechanism-driven treatment strategy for SYNGAP1-related neurodevelopmental disorders, addressing sleep and behavioral dysfunction at the synaptic circuitry level.· Repurposing of an FDA Approved Drug: Utilizes Perampanel (PMP), an already FDA-approved...

Published: 3/13/2026 | Inventor(s): Shilpa Kadam

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Technology Classifications > Therapeutic Modalities

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 3/12/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity

Value Proposition· Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4· The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...

Published: 3/12/2026 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Sustained release formulations for fat reduction

Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems. White adipose...

Published: 3/13/2026 | Inventor(s): Laura Ensign, Yub Raj Neupane, Fatemeh Rajaii

Keywords(s):

Category(s): Clinical and Disease Specializations > Endocrinology > Thyroid Disorders, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Small Molecules

Intranasal Delivery of Testosterone Prodrugs to the CNS

Unmet NeedProstate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable but is treatable. The gold standard of care is androgen...

Published: 3/13/2026 | Inventor(s): Rana Rais, Barbara Slusher, Mark Markowski, Arindom Pal

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Small Molecules

1 2 3 4 5 6 7 8 9 10 ...